[go: up one dir, main page]

CY1109120T1 - Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης - Google Patents

Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης

Info

Publication number
CY1109120T1
CY1109120T1 CY20091100590T CY091100590T CY1109120T1 CY 1109120 T1 CY1109120 T1 CY 1109120T1 CY 20091100590 T CY20091100590 T CY 20091100590T CY 091100590 T CY091100590 T CY 091100590T CY 1109120 T1 CY1109120 T1 CY 1109120T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
vinfluinin
preparation
intentional administration
administration
Prior art date
Application number
CY20091100590T
Other languages
English (en)
Inventor
Elie Leverd
JOëL BOUGARET
Marie-Dominique Ibarra
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34630533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109120(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Publication of CY1109120T1 publication Critical patent/CY1109120T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μια φαρμακευτική σύνθεση της βινφλουνίνης που εμφανίζεται υπό τη μορφή ενός υδατικού και στείρου υδατικού διαλύματος ενός υδατοδιαλυτού άλατος της βινφλουνίνης σε pH που περιλαμβάνεται μεταξύ 3 και 4. Αφορά επίσης τη μέθοδο παρασκευής αυτής της σύνθεσης και τη χρήση αυτής ως φάρμακο προοριζόμενο για παρεντερική χορήγηση στη θεραπεία του καρκίνου.
CY20091100590T 2003-12-23 2009-06-03 Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης CY1109120T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0315312A FR2863891B1 (fr) 2003-12-23 2003-12-23 Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
EP04816422A EP1696913B1 (fr) 2003-12-23 2004-12-17 Composition pharmaceutique de vinflunine destinée à l'administration parentérale, procédé de préparation et utilisation

Publications (1)

Publication Number Publication Date
CY1109120T1 true CY1109120T1 (el) 2014-07-02

Family

ID=34630533

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100590T CY1109120T1 (el) 2003-12-23 2009-06-03 Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης

Country Status (35)

Country Link
US (1) US20070155768A1 (el)
EP (1) EP1696913B1 (el)
JP (2) JP5226220B2 (el)
KR (1) KR101166347B1 (el)
CN (2) CN1897940A (el)
AR (1) AR047346A1 (el)
AT (1) ATE424201T1 (el)
AU (1) AU2004314154B2 (el)
BR (1) BRPI0418005B8 (el)
CA (1) CA2551493C (el)
CR (1) CR8473A (el)
CY (1) CY1109120T1 (el)
DE (1) DE602004019809D1 (el)
DK (1) DK1696913T3 (el)
EC (1) ECSP066663A (el)
ES (1) ES2323374T3 (el)
FR (1) FR2863891B1 (el)
HK (1) HK1089105A1 (el)
IL (1) IL176404A (el)
MA (1) MA28237A1 (el)
MX (1) MXPA06007208A (el)
MY (1) MY139643A (el)
NI (1) NI200600146A (el)
NO (1) NO336427B1 (el)
NZ (1) NZ548028A (el)
OA (1) OA13348A (el)
PL (1) PL1696913T3 (el)
PT (1) PT1696913E (el)
RU (1) RU2362557C2 (el)
SI (1) SI1696913T1 (el)
TN (1) TNSN06197A1 (el)
TW (1) TWI334352B (el)
UA (1) UA83888C2 (el)
WO (1) WO2005070425A1 (el)
ZA (1) ZA200605201B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
US20110015221A1 (en) * 2003-12-23 2011-01-20 Pierre Fabre Medicament Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
FR2910812B1 (fr) 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
FR2912406B1 (fr) * 2007-02-13 2009-05-08 Pierre Fabre Medicament Sa Sels cristalins anhydres de vinflunine, procede de preparation et utilisation en tant que medicament et moyen de purification de la vinflunine.
EP1997534A1 (en) * 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
CN101129374B (zh) * 2007-06-26 2010-09-08 齐鲁制药有限公司 长春氟宁药物组合物及其制备方法与应用
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
CN101607968A (zh) * 2008-06-17 2009-12-23 江苏豪森药业股份有限公司 长春氟宁盐、其制备方法及其药物组合物
KR101844623B1 (ko) * 2011-03-29 2018-04-02 사노피 안정성이 향상된 오타믹사반 제제
ES2823281T3 (es) 2015-08-01 2021-05-06 Sun Pharmaceutical Ind Ltd Forma de dosificación del fármaco alcaloide vinca
US20190307741A1 (en) * 2016-07-06 2019-10-10 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307100A (en) * 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
US4619935A (en) * 1983-03-17 1986-10-28 Eli Lilly And Company Stable oncolytic formulations
HU195513B (en) * 1984-10-16 1988-05-30 Richter Gedeon Vegyeszet Process for producing stable solutions of alkaloides with bis-indole skeleton
FR2597750B1 (fr) * 1986-04-25 1989-06-02 Pf Medicament Solution aqueuse stable de sulfate de vincristine
IL83086A (en) * 1987-07-06 1991-03-10 Teva Pharma Stable,injectable solutions of vincristine salts
US4923876A (en) * 1988-04-18 1990-05-08 Cetus Corporation Vinca alkaloid pharmaceutical compositions
CA2001643A1 (en) * 1988-12-23 1990-06-23 Richard L. Wolgemuth Preservative-free multi-dose vincristine solution
HU204995B (en) * 1989-11-07 1992-03-30 Richter Gedeon Vegyeszet Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes
JPH06100452A (ja) * 1993-04-06 1994-04-12 Asta Medica Ag イホスファミド用の製薬学的容器
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
DE19706255C2 (de) * 1997-02-18 2000-11-30 Schott Glas Sterilisierbarer Glasbehälter für medizinische Zwecke, insbesondere zur Aufbewahrung pharmazeutischer oder diagnostischer Produkte
FR2761990B1 (fr) * 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
JP3642492B1 (ja) * 2003-10-31 2005-04-27 小野薬品工業株式会社 オザグレルナトリウム含有水溶液を充填してなる注射用容器
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Also Published As

Publication number Publication date
MY139643A (en) 2009-10-30
IL176404A (en) 2010-11-30
NO20063277L (no) 2006-07-14
CN1897940A (zh) 2007-01-17
WO2005070425A1 (fr) 2005-08-04
FR2863891B1 (fr) 2006-03-24
JP5710462B2 (ja) 2015-04-30
JP5226220B2 (ja) 2013-07-03
RU2362557C2 (ru) 2009-07-27
KR20060124624A (ko) 2006-12-05
BRPI0418005A (pt) 2007-04-17
TNSN06197A1 (fr) 2007-11-15
NI200600146A (es) 2006-12-12
PT1696913E (pt) 2009-06-05
JP2007515461A (ja) 2007-06-14
EP1696913B1 (fr) 2009-03-04
ECSP066663A (es) 2006-10-25
FR2863891A1 (fr) 2005-06-24
CA2551493A1 (fr) 2005-08-04
BRPI0418005B1 (pt) 2019-11-26
AU2004314154B2 (en) 2011-03-24
UA83888C2 (ru) 2008-08-26
CA2551493C (fr) 2012-12-04
RU2006126708A (ru) 2008-01-27
MXPA06007208A (es) 2006-08-18
IL176404A0 (en) 2006-10-05
NO336427B1 (no) 2015-08-17
AR047346A1 (es) 2006-01-18
MA28237A1 (fr) 2006-10-02
BRPI0418005B8 (pt) 2021-05-25
JP2012102120A (ja) 2012-05-31
DE602004019809D1 (de) 2009-04-16
CN101695474A (zh) 2010-04-21
DK1696913T3 (da) 2009-06-29
PL1696913T3 (pl) 2009-08-31
SI1696913T1 (sl) 2009-08-31
NZ548028A (en) 2010-01-29
EP1696913A1 (fr) 2006-09-06
ZA200605201B (en) 2007-09-26
TW200531717A (en) 2005-10-01
CR8473A (es) 2006-11-24
HK1089105A1 (en) 2006-11-24
TWI334352B (en) 2010-12-11
KR101166347B1 (ko) 2012-07-18
OA13348A (fr) 2007-04-13
US20070155768A1 (en) 2007-07-05
ATE424201T1 (de) 2009-03-15
AU2004314154A1 (en) 2005-08-04
ES2323374T3 (es) 2009-07-14

Similar Documents

Publication Publication Date Title
CY1109120T1 (el) Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης
CY1119381T1 (el) Παραγωγα 2-μεθυλομορφολινο πυριδο-, πυραζο- και πυριμιδο-πυριμιδινης ως αναστολεις mtor
CY1116075T1 (el) Νεες συνθεσεις λιποσωματων
CY1120564T1 (el) Υδατικα εναιωρηματα tmc278
CY1117656T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
TW200500067A (en) Salts of codrugs and uses related thereto
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
IS8132A (is) Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar
ATE405564T1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
WO2005072061A3 (en) Conjugates for cancer therapy and diagnosis
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1106361T1 (el) Νανοσωματιδια για τη χορηγηση ενepγων συστατικων, μεθοδος παραγωγης των αναφepθεντων σωματιδιων και συνθεση που τα πepιεχει
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
SE0300098D0 (sv) Use of cyclin D1 inhibitors
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105105T1 (el) Χρηση του διστροντιου αλατος του 2-[ν,ν-δι(καρβοξυμεξυλ) amino]- 3-κυανο-4-καρβοξυμεθυλ-θειοφενο-5-καρβοξυλικου οξεος για τη ληψη φαρμακων που προοριζονται για τη θεραπεια γαστρο-δωδεκαδακτυλικων πονων